The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) support...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephenson, Diane, Hill, Derek, Cedarbaum, Jesse M., Tome, Maria, Vamvakas, Spiros, Romero, Klaus, Conrado, Daniela J., Dexter, David T., Seibyl, John, Jennings, Danna, Nicholas, Timothy, Matthews, Dawn, Xie, Zhiyong, Imam, Syed, Maguire, Paul, Russell, David, Gordon, Mark Forrest, Stebbins, Glenn T., Somer, Ed, Gallagher, Jill, Roach, Arthur, Basseches, Peter, Grosset, Donald, Marek, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700608/
https://www.ncbi.nlm.nih.gov/pubmed/31306141
http://dx.doi.org/10.3233/JPD-191648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700608/
https://www.ncbi.nlm.nih.gov/pubmed/31306141
http://dx.doi.org/10.3233/JPD-191648

Ejemplares similares